Table 3.
Base case clinical outcomes
| Outcome | Dapagliflozin plus Standard Therapy | Standard Therapy | Incremental |
|---|---|---|---|
| Survival | |||
| 1-yr survival, % | 99 | 98 | 0.6 |
| 5-yr survival, % | 90 | 85 | 4 |
| 10-yr survival, % | 71 | 63 | 8 |
| Total LYs gained, undiscounted (95% CrI) | 15.5 (11.2 to 18.2) | 13.8 (9.9 to 16.5) | 1.7 (0.7 to 2.5) |
| Mean time in each CKD stage (eGFR range, ml/min per 1.73 m2), yr (95% CrI) | |||
| CKD G2 (60–89) | 0.9 (0.6 to 1.0) | 0.7 (0.6 to 0.9) | 0.1 (0.0 to 0.2) |
| CKD G3 (30–59) | 7.1 (5.2 to 8.2) | 5.8 (4.4 to 7.0) | 1.3 (0.7 to 3.6) |
| CKD G4 (15–29) | 4.1 (2.8 to 5.0) | 3.9 (2.7 to 4.9) | 0.3 (–0.1 to 0.6) |
| CKD G5 (not on KRT, <15) | 0.5 (0.3 to 0.7) | 0.5 (0.3 to 0.7) | 0.0 (–0.1 to 0.1) |
| KRT | 2.9 (1.9 to 3.6) | 2.8 (1.9 to 3.6) | 0.0 (–0.4 to 0.5) |
| Event incidence, per 1000 patients | |||
| Hospitalization for heart failure | 81 | 100 | −19 |
| Acute decline in kidney function | 363 | 390 | −28 |
| Adverse eventsa | 936 | 746 | 190 |
The outcomes presented here are taken from the UK analysis; there is minimal variation in the values for Germany and Spain corresponding to country-specific life tables. Incremental values may not correspond exactly to the treatment arms due to rounding. LY, life year; 95% CrI, 95% credibility interval.
a
Adverse events include volume depletion, hypoglycemic events, fractures, diabetic ketoacidosis, and amputation.